Emergent BioSolutions, Inc., plans Michigan expansion

Emergent BioSolutions, Inc., the makers of the only U.S. Food and Drug Administration approved anthrax vaccine, recently announced plans for a major upgrade to its operations in Lansing, Michigan.

The Rockville, Maryland-based biopharmaceutical said that it would soon begin work on a $108 million expansion plan aimed for completion in 2016, according to LansingStateJournal.com.

Emergent BioSolutions, Inc., will build a new $9.6 million administration building at its Lansing site and spend an additional $4 million on infrastructure upgrades by next year. The plans will support new renovations for the next several years that include a new warehouse, science building and other improvements that the company said that it will need in order to train and recruit new employees.

"We're cramped for space and we've added a number of employees over the years," Mark Alley, the senior director of global protective services and public affairs, said, LansingStateJournal.com reports. "In terms of our ability to do laboratory work, we're running out of room."

Alley said that the company would fund the entire project, although it has applied for $6.4 million in local brownfield incentives to help reimburse its expenses through 2041. The project is expected to generate nearly $3.6 million in new property taxes and is contingent on approval of the brownfield plan.

The first phase of the plan should take 18 months for completion and includes a new three story, 33,000-square-foot administration center. The building is to be constructed on the site of an existing parking lot and will include water and steam system upgrades.